A study for protective mechanisms of VGF, a neurosecretory peptide, in glaucomatous optic nerve degeneration
Project/Area Number |
26462694
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Ophthalmology
|
Research Institution | Gifu Pharmaceutical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
原 英彰 岐阜薬科大学, 薬学部, 教授 (20381717)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 網膜神経節細胞 / 小胞体ストレス / 緑内障 |
Outline of Final Research Achievements |
In this study, we investigated the involvements of VGF in a mouse experimental glaucoma (optic nerve crush) model. Vgf mRNA increased in retina at the peak of 3 days after optic nerve crush. The VGF protein showed an increase after 7 days after optic nerve crush. Intravitreal administration of VGF peptide (AQEE 30) significantly suppressed retinal ganglion cell death after optic nerve crush. This finding suggests that VGF has a protective effect against retinal ganglion cell disorder.
|
Report
(4 results)
Research Products
(3 results)